EUCTR2012-001144-22-FR进行中（未招募）1 期
A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA, INITIALLY UNRESECTABLE. - ANTHALYA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ROCHE SAS
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Written, informed consent obtained prior to any study-specific procedure
- •- Woman aged = 18 years
- •- Histologically confirmed and documented, by peritoneal biopsy, high risk epithelial ovarian carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma
- •- Patients are required to be deemed by a surgeron experienced in the management of ovarian cancer not to be eligible for primary complete debulking surgery during a laparoscopic procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •* Patient with:
- •non-epithelial ovarian cancer
- •ovarian tumour with low malignant potential (i.e. borderline tumour)
- •inadequate bone marrow, liver or renal function
- •Carcinosarcoma
- •* Previous systemic therapy for ovarian cancer (i.e. chemo-, immuno-, hormonal, monoclonal antibody or tyrosine kinase inhibitor therapy)
- •* Planned intraperitoneal cytotoxic chemotherapy
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002551-15-ITASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.132
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2018-002551-15-ESAstellas Pharma Global Development, Inc. (APGD)141
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancer.First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.MedDRA version: 21.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104CTIS2024-510985-17-00Astellas Pharma Global Development Inc.396
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002551-15-FRAstellas Pharma Global Development, Inc. (APGD)141
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002551-15-IEAstellas Pharma Global Development, Inc. (APGD)369